Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) announced acceptance into the NVIDIA Connect Program on November 20, 2025.

Participation provides access to NVIDIA GPU-accelerated developer tools, SDKs/APIs, technical guidance, and co-marketing support to support computational-biology workflows such as target identification, protein-structure modeling, and preclinical data analytics for programs including HT-001, HT-KIT, HT-ALZ, and metabolic-disease initiatives.

The company said the program is expected to reduce computational bottlenecks, speed modeling, and strengthen AI-driven R&D and decision-making.

Insights

AI-accelerated R&D Strategist

Hoth gains technical and marketing resources from NVIDIA to accelerate computational biology workflows.

Hoth will receive access to NVIDIA GPU-accelerated developer tools, SDKs, APIs, technical guidance, and co-marketing support, which directly targets computational tasks named in the release: target identification, protein-structure modeling, and preclinical data analytics. The company lists specific programs that may benefit: HT-001, HT-KIT, HT-ALZ, and metabolic-disease initiatives, so the mechanism of value is faster model training, reduced compute bottlenecks, and improved algorithmic support for those programs.

Dependencies and risks are explicit and limited to integration and execution: benefits rely on effective deployment of the provided SDKs and GPU tooling and on the company’s ability to embed these capabilities into its workflows. Marketing visibility from co-marketing is a factual, non‑quantified benefit and does not guarantee clinical or regulatory progress.

Watch for concrete follow-ups such as technical integration milestones, announcements showing improved modeling speed or expanded use of NVIDIA SDKs across the named programs, and any joint technical case studies or co-marketing materials; these items will indicate whether the stated operational benefits materialize in the near term after Nov. 20, 2025.

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms.

Acceptance into the NVIDIA Connect Program provides Hoth Therapeutics with access to a suite of accelerated computing resources, technical guidance, and marketing support, enabling the company to further strengthen its AI-powered research initiatives across its therapeutic pipeline.

Strategic AI Integration to Enhance Hoth's R&D Capabilities

Through the NVIDIA Connect Program, Hoth Therapeutics will gain access to:

• NVIDIA GPU-accelerated developer tools to enhance computational-biology workflows, including target identification, protein-structure modeling, and preclinical data analytics.
• Technical expertise, SDKs, and APIs that can support algorithmic modeling across Hoth's programs, including HT-001 (pruritus reduction), HT-KIT (mast-cell modulation), HT-ALZ (GDNF-based Alzheimer's therapy), and its metabolic-disease initiatives developed in partnership with leading academic institutions.
• Co-marketing and technology enablement opportunities, increasing visibility of Hoth's AI-driven approach to drug development.

Positioning Hoth for Accelerated Time-to-Market

Participation in the Connect Program is expected to streamline key aspects of Hoth's R&D strategy, reducing computational bottlenecks and enhancing predictive modeling.

"Acceptance into the NVIDIA Connect Program is a meaningful milestone for Hoth," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "NVIDIA is a global leader in accelerated computing and AI, and this partnership will enable us to leverage cutting-edge technology to enhance our drug-development programs, increase modeling speed, and improve the efficiency of our preclinical and clinical decision-making."

About the NVIDIA Connect Program
The NVIDIA Connect Program is a global initiative that enables ISVs, software developers, and service providers to accelerate time-to-market using NVIDIA's latest technology innovations. Members receive access to technical tools, preferred pricing, co-marketing opportunities, and a comprehensive developer ecosystem.

About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct.Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-accepted-into-nvidia-connect-program-expanding-its-ai-and-accelerated-computing-capabilities-302621313.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What does Hoth Therapeutics (HOTH) joining the NVIDIA Connect Program mean for investors?

It provides access to NVIDIA GPU tools, SDKs/APIs, technical support, and co-marketing that may accelerate Hoth's AI-driven R&D workflows.

Which Hoth drug programs will use NVIDIA accelerated computing?

The company said HT-001, HT-KIT, HT-ALZ, and its metabolic-disease initiatives will benefit from the NVIDIA tools and technical support.

How will NVIDIA GPU resources affect Hoth's research timelines?

Hoth indicated the program is expected to reduce computational bottlenecks and increase modeling speed, potentially streamlining R&D decision-making.

Does Hoth expect any marketing benefits from the NVIDIA Connect Program?

Yes; acceptance includes co-marketing and technology enablement opportunities to increase visibility of Hoth's AI-driven approach.

When was Hoth Therapeutics accepted into the NVIDIA Connect Program?

Hoth announced acceptance on November 20, 2025.

Will NVIDIA technical support include software development kits for Hoth (HOTH)?

Yes; the company will gain access to technical expertise, SDKs, and APIs to support algorithmic modeling across its programs.